Earnings Feed
Start Free
Werewolf Therapeutics, Inc.·4

Jun 3, 6:42 PM ET

EVNIN LUKE 4

Research Summary

AI-generated summary

Updated

Werewolf Therapeutics (HOWL) Director Luke Evnin Sells Shares

What Happened
Luke Evnin, a director (via affiliated investment vehicles), reported the sale of 139,803 Werewolf Therapeutics (HOWL) shares in three open‑market transactions on June 1–3, 2026. The trades generated aggregate proceeds of roughly $63,629 (80,459 shares for $37,816 on 6/1; 29,595 shares for $13,318 on 6/2; 29,749 shares for $12,495 on 6/3). These were sales (code S) and not purchases — sales are often routine and do not necessarily indicate company outlook.

Key Details

  • Dates & reported prices:
    • 2026-06-01: 80,459 shares at $0.47 (reported) — proceeds $37,816. (Footnote: weighted‑average and per-trade prices ranged; see filing.)
    • 2026-06-02: 29,595 shares at $0.45 — proceeds $13,318. (Weighted‑average; range noted in footnotes.)
    • 2026-06-03: 29,749 shares at $0.42 — proceeds $12,495. (Weighted‑average; range noted in footnotes.)
  • Sales were executed by affiliated entities: MPM Asset Management LLC (AM LLC), MPM BioVentures 2014 (BV 2014), BV 2014(B), AM BV2014, and MPM Oncology Innovations Fund (MPM OIF). Each day's sale is broken down across those entities in the filing.
  • Remaining reported holdings (across the related entities) after these transactions: the filing lists per-entity totals (final aggregate shown in the filing: 54,910; 346,707; 23,123; 11,931; and 75,854 shares for the five entities, respectively — see filing for the detailed per-entity breakdown).
  • Footnotes of note:
    • Transactions were effected pursuant to a Rule 10b5‑1 trading plan dated March 26, 2026.
    • Reported prices are weighted averages; the filing provides price ranges and offers to supply the per‑trade pricing on request.
    • The reporting person (Luke Evnin) is a member/manager/director of the listed entities and disclaims direct beneficial ownership except to the extent of any pecuniary interest.
  • Filing timeliness: the report was filed with an accession date of 2026-06-03 for transactions through 2026-06-01–06-03; no late‑filing notation is indicated in the summary provided here.

Context

  • These sales were done by affiliated investment vehicles rather than direct, personal one-off trades. Footnotes show institutional holdings and Evnin’s managerial roles; he disclaims beneficial ownership except for pecuniary interest.
  • Because the trades were executed under a 10b5‑1 plan, they were pre‑scheduled, which is a common mechanism to avoid timing accusations; this is factual information, not a statement about motivation.